Protalix BioTherapeutics Statistics
Share Statistics
Protalix BioTherapeutics has 73.63M shares outstanding. The number of shares has increased by 0.8% in one year.
| Shares Outstanding | 73.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 68.07M |
| Failed to Deliver (FTD) Shares | 67 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 3.10M, so 4.21% of the outstanding shares have been sold short.
| Short Interest | 3.10M |
| Short % of Shares Out | 4.21% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 22.71 |
Valuation Ratios
The PE ratio is 14.46 and the forward PE ratio is 2.13. Protalix BioTherapeutics 's PEG ratio is 0.02.
| PE Ratio | 14.46 |
| Forward PE | 2.13 |
| PS Ratio | 1.83 |
| Forward PS | 1 |
| PB Ratio | 3.58 |
| P/FCF Ratio | -48.71 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Protalix BioTherapeutics Inc. has an Enterprise Value (EV) of 122.82M.
| EV / Earnings | 14.78 |
| EV / Sales | 1.88 |
| EV / EBITDA | 10.54 |
| EV / EBIT | 11.74 |
| EV / FCF | -49.78 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.54 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.65 |
| Total Debt / Capitalization | 39.22 |
| Cash Flow / Debt | -0.06 |
| Interest Coverage | 3.29 |
Financial Efficiency
Return on equity (ROE) is 0.25% and return on capital (ROIC) is 16.96%.
| Return on Equity (ROE) | 0.25% |
| Return on Assets (ROA) | 0.1% |
| Return on Capital (ROIC) | 16.96% |
| Revenue Per Employee | 314.88K |
| Profits Per Employee | 39.96K |
| Employee Count | 208 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.21 |
Taxes
| Income Tax | 254.00K |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by 40% in the last 52 weeks. The beta is 0.67, so Protalix BioTherapeutics 's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | 40% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 72.75 |
| Average Volume (20 Days) | 432.78K |
Income Statement
In the last 12 months, Protalix BioTherapeutics had revenue of 65.49M and earned 8.31M in profits. Earnings per share was 0.12.
| Revenue | 65.49M |
| Gross Profit | 42.51M |
| Operating Income | 10.46M |
| Net Income | 8.31M |
| EBITDA | 11.65M |
| EBIT | 10.46M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 23.63M in cash and 26.28M in debt, giving a net cash position of -2.65M.
| Cash & Cash Equivalents | 23.63M |
| Total Debt | 26.28M |
| Net Cash | -2.65M |
| Retained Earnings | -381.55M |
| Total Assets | 61.56M |
| Working Capital | 23.63M |
Cash Flow
In the last 12 months, operating cash flow was -1.32M and capital expenditures -1.15M, giving a free cash flow of -2.47M.
| Operating Cash Flow | -1.32M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | -2.47M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 64.91%, with operating and profit margins of 15.97% and 12.69%.
| Gross Margin | 64.91% |
| Operating Margin | 15.97% |
| Pretax Margin | 13.08% |
| Profit Margin | 12.69% |
| EBITDA Margin | 17.79% |
| EBIT Margin | 15.97% |
| FCF Margin | -3.77% |
Dividends & Yields
PLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.53% |
| FCF Yield | -1.54% |
Analyst Forecast
The average price target for PLX is $10, which is 360.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 360.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 20, 2019. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 20, 2019 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -4.58 |
| Piotroski F-Score | 4 |